Literature DB >> 2139281

Hepatitis B: global importance and need for control.

J E Maynard1.   

Abstract

Hepatitis B is a disease of global importance, with greater than 300 million carriers of the virus world-wide. Hepatitis B virus (HBV) is the cause of up to 80% of cases of primary liver cancer, the single most important cause of mortality globally. In countries where HBV carrier rates reach 10%, HBV infection may account for 3% of total mortality, a level which exceeds polio-related mortality before the introduction of polio vaccine. The only means by which hepatitis B can be eventually eliminated is mass vaccination of infants with hepatitis B vaccine as part of the Expanded Programme on Immunization (EPI) in areas of the world where the HBV carrier rate exceeds 2.5%. With recent dramatic increases in hepatitis B vaccine production and decreases in per-dose price, there are grounds for optimism that global HBV infection rates may be reduced by as much as 90% over the next 10 years.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139281     DOI: 10.1016/0264-410x(90)90209-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  72 in total

Review 1.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

2.  Hepatitis B in Canada: the case for universal vaccination. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1992-01-01       Impact factor: 8.262

3.  Targeted versus universal vaccination against hepatitis B: A paradigm shift.

Authors:  J M Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1993-05

4.  The dynamics of hepatitis B virus infection.

Authors:  R J Payne; M A Nowak; B S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

5.  Comparison of the nucleic acid-based crosslinking hybridization assay and the branched DNA signal amplification assay in the quantitative measurement of serum hepatitis B virus DNA.

Authors:  S J Hwang; R H Lu; M L Wood; Y J Wang; F Y Chang; S D Lee
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

6.  Predictors of hepatitis B immunization status in Korean American children.

Authors:  Y O Kim; S Telleen
Journal:  J Immigr Health       Date:  2001-10

7.  The war on cancer: a report from the front lines.

Authors:  Gavin Melmed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

8.  Seroprevalence of Hepatitis B, Hepatitis C, and Human T-Cell Lymphotropic Virus Infections in HIV-Infected Patients in Sierra Leone.

Authors:  George A Yendewa; Foday Sahr; Antonio Aguilera; Sulaiman Lakoh; Momodu Sesay; Gibrilla F Deen; Lucia Patiño; Eva Poveda; Robert A Salata
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

9.  Immune mediated crescentic MPGN secondary to HBV infection: A rare presentation for a common infection.

Authors:  Aswani Srinivas Mareddy; Dharshan Rangaswamy; Mahesha Vankalakunti; Ravindra Prabhu Attur; Shankar Prasad Nagaraju; Neeraja Koti
Journal:  Australas Med J       Date:  2016-01-31

10.  Hepatitis B virus infection among Chinese residents in the United Kingdom.

Authors:  M Kawsar; B T Goh
Journal:  Sex Transm Infect       Date:  2002-06       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.